Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04323735 · ClinicalTrials.gov registry record · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
A Phase 2 study of Neurogenic Bladder, sponsored by Medstar Health Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 1
- Study location
NCT04323735: Recruiting Phase 2 study of Neurogenic Bladder, sponsored by Medstar Health Research Institute.
NCT04323735 is a Phase 2 study of Neurogenic Bladder that is actively recruiting participants, run by Medstar Health Research Institute. The registered enrollment target is 182 participants, above the 82-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (122% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04323735, a Phase 2 study of Neurogenic Bladder, is actively recruiting participants, sponsored by Medstar Health Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
Primary Outcome
Will measure change in urinary symptoms for those that use an indwelling catheter. Higher score may mean worse outcomes. (local urine collection participants only)
Conditions Studied
Interventions
- DRUG Culturelle 10 Billion CFU Capsule
Study Locations (1)
District of Columbia
- MedStar National Rehabilitation Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What NCT04323735 shows while recruiting
NCT04323735 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, above the 82-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (122% higher).
The record links to 1 condition, with Neurogenic Bladder appearing as the primary indexed condition, and to 1 intervention - of which Culturelle 10 Billion CFU Capsule is the first listed.
NCT04323735 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04323735 about?
NCT04323735 is a clinical study titled "Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters". The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intrave...
What is the current status of trial NCT04323735?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2020-01-10. Estimated completion is 2026-09.
What conditions does trial NCT04323735 study?
This clinical trial studies the following conditions: Neurogenic Bladder.
What interventions are being tested in trial NCT04323735?
The interventions under investigation include: Culturelle 10 Billion CFU Capsule (DRUG).
Who is sponsoring clinical trial NCT04323735?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04323735 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04323735's enrollment target sits among peer trials
182 2nd of 16 the highest of 16 other Neurogenic Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurogenic Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intravesical LGG VS Saline Bladder Wash RCT
RECRUITING · Phase 2
-
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
RECRUITING · Early Phase 1
-
Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms
RECRUITING
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
Concomitant Renal and Urinary Bladder Allograft Transplantation
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
- NCT06084936 · 182 participants · Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI